Transrectal ultrasound guided prostate biopsy (TRUSgBX) is a common diagnostic test for prostate cancer in the setting of an abnormal digital rectal examination or elevated prostate specific antigen. While TRUSgBX is known to have significant limitations, multiparametric MRI guided target biopsy methods have been shown to out-perform TRUSgBX for detection and diagnosis of clinically significant prostate cancers and to reduce detection of indolent cancers. The aim of this study is to determine the role of PIRADS V2 and TRUSgBX to predict presence of csPCa.
Dr. Alireza Ziaei is a Fellow in the Ferenc Jolesz National Center for Image-Guided Therapy Multidisciplinary Program. He joined Surgical Planning Laboratory at Brigham & Women’s Hospital, Harvard Medical School in 2016 and his primary research is on evaluating qualitative and quantitative multiparametric MRI in assessment of aggressive tumors. Other aspects of his research include analyzing images with segmentation and volumetric tools for measurements on MRI images using 3D Slicer software to develop an automated application to MRI guided biopsy and processing diagnostic imaging for surgical planning. Dr. Ziaei received his M.D. with high honors from Iran followed by Postdoctoral Fellowship at Schepens Research Institute, Massachusetts Eye & Ear at Harvard Medical School and Boston University School of Medicine, where he is trained and experienced in a wide spectrum of basic science to the bedside. Dr. Ziaei published and presented numerous articles in highly ranked peer reviewed journals and conferences, and his works has been recognized several times. He is a recipient of numerous awards including National Young Investigator Award, National Excellent Researchers and Best Article Symposium Awards.